Commonwealth Financial Services LLC Lowers Stock Position in Johnson & Johnson (NYSE:JNJ)

Commonwealth Financial Services LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.3% during the 2nd quarter, Holdings Channel reports. The firm owned 7,559 shares of the company’s stock after selling 342 shares during the quarter. Commonwealth Financial Services LLC’s holdings in Johnson & Johnson were worth $1,100,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Delos Wealth Advisors LLC boosted its stake in shares of Johnson & Johnson by 3,333.3% in the 2nd quarter. Delos Wealth Advisors LLC now owns 1,545 shares of the company’s stock worth $226,000 after buying an additional 1,500 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in Johnson & Johnson by 26.8% in the second quarter. EverSource Wealth Advisors LLC now owns 18,396 shares of the company’s stock worth $2,904,000 after purchasing an additional 3,887 shares during the last quarter. Fairscale Capital LLC bought a new position in Johnson & Johnson in the 2nd quarter valued at $712,000. First City Capital Management Inc. increased its position in shares of Johnson & Johnson by 3.0% during the 2nd quarter. First City Capital Management Inc. now owns 10,145 shares of the company’s stock valued at $1,483,000 after purchasing an additional 295 shares during the last quarter. Finally, Itau Unibanco Holding S.A. raised its stake in shares of Johnson & Johnson by 7.5% during the 2nd quarter. Itau Unibanco Holding S.A. now owns 3,018 shares of the company’s stock worth $441,000 after purchasing an additional 211 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.4 %

Shares of NYSE JNJ opened at $164.16 on Monday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The company has a market cap of $395.08 billion, a P/E ratio of 10.23, a P/E/G ratio of 2.71 and a beta of 0.53. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The business has a 50-day simple moving average of $161.30 and a two-hundred day simple moving average of $154.12.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. Johnson & Johnson’s revenue was up 4.3% compared to the same quarter last year. During the same period last year, the business earned $2.80 earnings per share. Research analysts anticipate that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were issued a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.02%. Johnson & Johnson’s payout ratio is currently 30.92%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on JNJ shares. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Morgan Stanley raised their price target on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. The Goldman Sachs Group dropped their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research report on Friday. Finally, Sanford C. Bernstein increased their price target on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.21.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.